Skip to Content

Clopidogrel/Acetylsalicylic acid Teva

Active Substance: clopidogrel / acetylsalicylic acid
Common Name: clopidogrel / acetylsalicylic acid
ATC Code: B01AC30
Marketing Authorisation Holder: Teva Pharma B.V.
Active Substance: clopidogrel / acetylsalicylic acid
Status: Withdrawn
Authorisation Date: 2014-09-01
Therapeutic Area: Acute Coronary Syndrome Myocardial Infarction
Pharmacotherapeutic Group: Film-coated tablet

Therapeutic Indication

Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Clopidogrel/Acetylsalicylic acid Teva is a fixed‑dose combination medicinal product for continuation of therapy in:

  • Non‑ST segment elevation acute coronary syndrome (unstable angina or non‑Q‑wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention

ST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy

The marketing authorisation for Clopidogrel/Acetylsalicylic acid Teva has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.